• What is your policy on shareholder returns?

    We are not currently considering dividends.
    Our priority is to advance research and development and bring our products to market as early as possible. Once we reach a stage where revenue can be generated on a continuous basis, we will reassess our approach to shareholder returns.

  • Do you disclose quarterly financial results?

    For the time being, we plan to hold earnings briefings twice a year—at mid‑term and fiscal year‑end—together with detailed presentation materials.
    From the next fiscal year onward, we will consider quarterly earnings disclosures based on the progress of our clinical programs.

  • How do you disclose information related to patents?

    Patent applications are generally published approximately 18 months after filing, and registration follows examination by the relevant authorities.
    We disclose information on patent filings, publications, and registrations in documents such as our financial results.
    However, we do not provide timely disclosure for the following reasons:

    1. Patent filings, publications, or registrations do not have a direct impact on our financial performance.
    2. Disclosing the fact that a patent has been filed may provide strategic information to competitors.

    The reference in page 2 of our financial results announcement dated July 14, 2025 (for the third quarter of the fiscal year ending August 2025), “New patent application filed in January 2024,” refers to the use‑patent application concerning the combination therapy of rogocekib with other anticancer agents, published by the World Intellectual Property Organization (WIPO) on July 17, 2025.

    We will continue to provide appropriate disclosures in accordance with this policy.